HER2-改变的非小细胞肺癌:从当前方法到新兴策略的旅程
Giorgia Ferrari1, Benedetta Del Rio1, Silvia Novello1
1Department of Oncology, University of Turin, San Luigi Hospital, 10124 Orbassano, Italy.
Cancers
|June 19, 2024
概括
特拉斯图祖马布德鲁克斯泰坎为先进的HER2-改变的非小细胞肺癌 (NSCLC) 提供了突破性进展,显示出显著的疗效,特别是在大脑转移中. 这种向治疗现在是预先治疗的患者的关键治疗选择.
科学领域:
- 在瘤学瘤学.
- 医学遗传学 医学遗传学
- 药理学 药理学是指药理学的学科.
背景情况:
- 目前对先进的HER2-改变NSCLC的治疗标准包括化疗,通常是免疫疗法.
- 之前的泛HER激素氨酸激酶抑制剂的成功程度有限.
- 针对HER2的抗体-药物合体 (ADC),如特拉斯图祖马布德鲁克斯坦,显示出显著的前景.
研究的目的:
- 审查当前和新兴的策略来管理HER2-改变的NSCLC.
- 突出未满足的需求,特别是在治疗大脑转移时.
- 总结一下trastuzumab deruxtecan在高级NSCLC中的影响.
主要方法:
- 对DESTINY-Lung01和DESTINY-Lung02试验进行了审查.
- 对HER2-改变的NSCLC中trastuzumab deruxtecan的临床数据的分析.
- 评估新兴的组合疗法.
主要成果:
- 特拉斯图祖马布德鲁克斯泰坎在HER2突变性NSCLC中显示出有希望的结果,包括高内活性.
- 特拉斯图祖马布德鲁克斯获得了对预先治疗的,先进的HER2突变NSCLC的监管批准.
- 对前期治疗的HER2阳性固体瘤中使用trastuzumab deruxtecan获得FDA的加速批准.
结论:
- 特拉斯图祖马布德鲁克斯泰坎代表了HER2改变的NSCLC治疗的重大进展.
- 结合疗法正在探索在晚期疾病中的协同效应.
- 解决大脑转移的治疗仍然是一个关键的未满足的需求.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.7K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Tumor Immunotherapy
511
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
511
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K